Introduction

Sunday 2nd and Monday 3rd October 2022 - a face to face workshop over 2 half-days prior to the start of the 2022 Joint Meeting, Amsterdam, Netherlands.
For details of the Joint Meeting and the separate registration process, please click here.

The current regulatory landscape for the development of peptides and oligonucleotide drugs may lead companies to perform a variety of small molecule-focussed ADME studies in support of filing packages. The aim of this workshop is for member company scientists to discuss and exchange ideas and experience of peptide and oligonucleotide ADME related challenges (active participation is expected). Addressing the question,

“if the current activities are suitable for these modalities, should science-driven decisions on the development of such molecules be implemented more in the industry”.

If you work in the drug development of peptides and/or oligonucleotides, and have such questions (or additional ones), please join the Workshop.

POW22 will start with lunch on Sunday 2nd in the Victoria Hotel and run until early evening, after which we will switch to networking mode in the true traditions of the DMDG. The Workshop will then restart in the morning of Monday 3rd and run until noon when those attending the 2022 Joint Meeting can then transfer to that venue.

The cost to attend the workshop is 495 EUR which includes

  • Registration for the POW22

  • Arrival lunch on 2nd October

  • Overnight accommodation (including breakfast) on the night of Sunday 2nd October in local hotels (Victoria Hotel or Movenpick Hotel)

  • Networking

The programme is in the making with the aspiration to provide talks touching upon: overview of the peptide and oligonucleotide landscapes, metabolism, DDI, analytical challenges and regulatory interactions.

If you have a hot topic you would like to be discussed (or a case story to share) then please contact the organisers:

Join the peptide/oligo discussion!!!